Sanofi: ambient psychosis

Strongly heckled during the last four sessions, Sanofi rebounded timidly this Friday on the Paris stock exchange. Like Deutsche Bank, which raised its recommendation on the pharmaceutical giant to ‘hold’, many investors consider the decline in the title “exaggerated”… If the broker is far from being thrilled by the file and considers that the current price levels do not really constitute an obvious buying opportunity in his eyes, he asserts that the maintenance of a ‘negative’ opinion at these levels seems clearly ‘abused’!… In recent days, the bad news around the pharmaceutical giant has piled up dramatically: The group must first deal with the halt in recruitment for clinical trials of tolebrutinib, an experimental treatment for certain forms of multiple sclerosis and myasthenia gravis, at following advice from the Independent Data Monitoring Committee. The latter requested the suspension of the recruitment of all trials,…